AR089957A1 - Combinaciones farmaceuticas, combinaciones sinergicas - Google Patents
Combinaciones farmaceuticas, combinaciones sinergicasInfo
- Publication number
- AR089957A1 AR089957A1 ARP130100415A ARP130100415A AR089957A1 AR 089957 A1 AR089957 A1 AR 089957A1 AR P130100415 A ARP130100415 A AR P130100415A AR P130100415 A ARP130100415 A AR P130100415A AR 089957 A1 AR089957 A1 AR 089957A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- solvated
- combinations
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261596893P | 2012-02-09 | 2012-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089957A1 true AR089957A1 (es) | 2014-10-01 |
Family
ID=48948043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130100415A AR089957A1 (es) | 2012-02-09 | 2013-02-08 | Combinaciones farmaceuticas, combinaciones sinergicas |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP2811989A1 (fr) |
JP (1) | JP2015509931A (fr) |
KR (1) | KR20150020160A (fr) |
CN (1) | CN104684549A (fr) |
AR (1) | AR089957A1 (fr) |
AU (1) | AU2013216864A1 (fr) |
CA (1) | CA2864173A1 (fr) |
HK (1) | HK1204966A1 (fr) |
IL (1) | IL234033A0 (fr) |
PH (1) | PH12014501814A1 (fr) |
SG (1) | SG11201404776PA (fr) |
TW (1) | TW201338772A (fr) |
WO (1) | WO2013119910A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
US9956194B2 (en) | 2014-12-03 | 2018-05-01 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
CN108290824B (zh) | 2015-10-23 | 2022-03-11 | B3Ar治疗股份有限公司 | 索拉贝隆两性离子及其应用 |
KR101868438B1 (ko) | 2017-04-13 | 2018-06-20 | (주) 성운파마코피아 | 아미드 유도체의 제조방법 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL124473C (fr) | 1960-07-26 | |||
US5677346A (en) | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
US6123961A (en) | 1996-09-25 | 2000-09-26 | Bridge Pharma, Inc. | Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin |
GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
GB9929297D0 (en) | 1999-12-11 | 2000-02-02 | Glaxo Group Ltd | Process |
GB0102407D0 (en) | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Process |
TW200800953A (en) * | 2002-10-30 | 2008-01-01 | Theravance Inc | Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine |
EP1424079A1 (fr) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine |
JP2010522751A (ja) * | 2007-03-29 | 2010-07-08 | メルク・シャープ・エンド・ドーム・コーポレイション | 下部尿路症状の治療のための併用療法 |
PE20091825A1 (es) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
EP2470021B1 (fr) | 2009-08-27 | 2014-10-22 | Merck Sharp & Dohme Corp. | Nouveaux agonistes de récepteurs adrénergiques bêta 3 dérivés de pyrrolidine |
JP5738871B2 (ja) * | 2009-10-07 | 2015-06-24 | メルク・シャープ・エンド・ドーム・コーポレイション | β3アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法 |
-
2013
- 2013-02-08 AU AU2013216864A patent/AU2013216864A1/en not_active Abandoned
- 2013-02-08 CN CN201380019041.9A patent/CN104684549A/zh active Pending
- 2013-02-08 EP EP13704702.3A patent/EP2811989A1/fr not_active Withdrawn
- 2013-02-08 TW TW102105243A patent/TW201338772A/zh unknown
- 2013-02-08 KR KR20147023969A patent/KR20150020160A/ko not_active Application Discontinuation
- 2013-02-08 CA CA2864173A patent/CA2864173A1/fr not_active Abandoned
- 2013-02-08 AR ARP130100415A patent/AR089957A1/es unknown
- 2013-02-08 WO PCT/US2013/025285 patent/WO2013119910A1/fr active Application Filing
- 2013-02-08 SG SG11201404776PA patent/SG11201404776PA/en unknown
- 2013-02-08 JP JP2014556709A patent/JP2015509931A/ja active Pending
-
2014
- 2014-08-10 IL IL234033A patent/IL234033A0/en unknown
- 2014-08-11 PH PH12014501814A patent/PH12014501814A1/en unknown
-
2015
- 2015-06-17 HK HK15105751.1A patent/HK1204966A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HK1204966A1 (en) | 2015-12-11 |
CN104684549A (zh) | 2015-06-03 |
PH12014501814A1 (en) | 2014-11-24 |
AU2013216864A1 (en) | 2014-09-11 |
SG11201404776PA (en) | 2014-09-26 |
EP2811989A1 (fr) | 2014-12-17 |
TW201338772A (zh) | 2013-10-01 |
KR20150020160A (ko) | 2015-02-25 |
IL234033A0 (en) | 2014-09-30 |
JP2015509931A (ja) | 2015-04-02 |
CA2864173A1 (fr) | 2013-08-15 |
WO2013119910A1 (fr) | 2013-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6680685A2 (es) | Combinaciones de agonistas del receptor beta 3-adrenergetico y antagonistas del receptor muscarínico para tratar vejiga hiperactiva | |
AR089957A1 (es) | Combinaciones farmaceuticas, combinaciones sinergicas | |
UY36660A (es) | Combinaciones de inhibidores de irak4 | |
ECSP11010948A (es) | Inhibidores de las enzimas de proteína cinasa activadas por | |
CL2009000815A1 (es) | Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria. | |
BR112017017135A2 (pt) | inibidores de tgf-beta | |
CO6440584A2 (es) | Compuestos diamida que tienen actividad como antagonistas de los receptores muscarínicos y como agonistas de los receptores adrenérgicos beta 2 | |
DOP2012000132A (es) | Composicion farmaceutica que comprende un agonista de glp-1 y metionina | |
CL2013002650A1 (es) | Compuestos derivados triciclicos con actividad sobre los receptores hormonales nucleares; composicion farmaceutica que los comprende; proceso de reparacion de compuestos intermediarios; y uso en el tratamiento del sida, insuficiencia adrenal aguda, enfermedad de addison, rinitis alergica, enfermedad de alzheimer, entre otros. | |
CL2013001677A1 (es) | Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia. | |
CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
CO6180437A2 (es) | Derivados de sulfonamida como agonistas adrenergicos y antagonistas muscarinicos | |
AR103680A1 (es) | Inhibidores selectivos de bace1 | |
CL2016003329A1 (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
CO6290644A2 (es) | Antagonista del receptor opioide selectivo kappa. | |
ES2689971T3 (es) | Uso de inhibidores de PDE7 para el tratamiento de los trastornos del movimiento | |
CL2012000263A1 (es) | Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc. | |
NI201800071A (es) | Compuestos de isoindol | |
AR086800A1 (es) | Composicion farmaceutica oftalmologica topica que contiene regorafenib | |
CO2017005806A2 (es) | Nuevos derivados de bencimidazol como agentes antihistamínicos | |
CL2013000599A1 (es) | Compuestos derivados de diciano-piridina, agonistas selectivos de adenosina a1, para su uso en un procedimiento para el tratamiento y/o profilaxis de glaucoma, glaucoma normotensivo, hipertension ocular y/o combinaciones de los mismos; y composicion farmaceutica que comprende a uno de dichos compuestos. | |
AR093851A1 (es) | Metodos para tratar la diabetes administrando un antagonista del receptor de glucagon en combinacion con un inhibidor de la absorcion del colesterol, combinacion | |
CL2019002808A1 (es) | Métodos para prevenir o tratar enfermedades oftálmicas. | |
AR097644A1 (es) | Composiciones farmacéuticas que contienen refametinib, uso y método de tratamiento | |
CL2009002146A1 (es) | Compuesto (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina y su sal mono-l-malato; su composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por nnr tal como trastornos del snc, inflamacion, trastornos inmunes, entre otros. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |